Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 2529 entries
View as:

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.

Phase: N/A Priority: Normal
NCT ID: NCT01582061 Org: User:
Start: 08/16/11 End: 01/26/17 Due: 01/26/18

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05429502 Org: User:
Start: 12/27/22 End: 02/26/25 Due: 02/26/26

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

Phase: N/A Priority: Normal
NCT ID: NCT01125800 Org: User:
Start: 02/28/11 End: 10/31/14 Due: 10/31/15

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Phase: N/A Priority: Normal
NCT ID: NCT00441155 Org: User:
Start: 11/30/06 End: 01/31/11 Due: 01/31/12

Study of Select Combinations in Adults With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04283526 Org: User:
Start: 11/30/20 End: 04/11/24 Due: 04/11/25

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01288092 Org: User:
Start: 03/31/12 End: - Due: -

Pelacarsen Roll-over Extension Program

Phase: N/A Priority: Normal
NCT ID: NCT06875973 Org: User:
Start: 05/20/25 End: 01/03/28 Due: 01/03/29

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT01358578 Org: User:
Start: 06/30/11 End: 07/31/13 Due: 07/31/14

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02240212 Org: User:
Start: 10/31/14 End: 02/07/17 Due: 02/07/18

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01487785 Org: User:
Start: 03/31/12 End: 07/31/14 Due: 07/31/15

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

Phase: N/A Priority: Normal
NCT ID: NCT01216085 Org: User:
Start: 08/31/10 End: 07/31/11 Due: 07/31/12

Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)

Phase: N/A Priority: Normal
NCT ID: NCT01757691 Org: User:
Start: 08/31/13 End: 05/31/14 Due: 05/31/15

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02381886 Org: User:
Start: 03/06/15 End: 02/01/26 Due: 02/01/27

Rainbow Extension Study

Phase: N/A Priority: Normal
NCT ID: NCT02640664 Org: User:
Start: 06/16/16 End: 04/21/22 Due: 04/21/23

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Phase: N/A Priority: Normal
NCT ID: NCT01034657 Org: User:
Start: 11/30/09 End: 08/31/12 Due: 08/31/13

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients

Phase: N/A Priority: Normal
NCT ID: NCT02130024 Org: User:
Start: 04/11/14 End: 11/15/17 Due: 11/15/18

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00846989 Org: User:
Start: 01/31/09 End: 04/30/09 Due: 04/30/10

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00302016 Org: User:
Start: 01/31/06 End: - Due: -

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Phase: N/A Priority: Normal
NCT ID: NCT06858332 Org: User:
Start: 03/31/25 End: 09/30/27 Due: 09/30/28

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Phase: N/A Priority: Normal
NCT ID: NCT01223898 Org: User:
Start: 06/30/10 End: 12/31/13 Due: 12/31/14

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT00076336 Org: User:
Start: 12/31/03 End: - Due: -

Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line

Phase: N/A Priority: Normal
NCT ID: NCT05734053 Org: User:
Start: 06/28/16 End: 09/08/22 Due: 09/08/23

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Phase: N/A Priority: Normal
NCT ID: NCT01643850 Org: User:
Start: 04/23/12 End: 12/21/18 Due: 12/21/19

Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

Phase: N/A Priority: Normal
NCT ID: NCT01135914 Org: User:
Start: 07/31/10 End: 03/31/13 Due: 03/31/14

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01479595 Org: User:
Start: 02/29/12 End: 02/28/15 Due: 02/28/16